Compare VIK & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIK | KVUE |
|---|---|---|
| Founded | 1997 | 2022 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Specialty Chemicals |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4B | 33.7B |
| IPO Year | 2023 | 2023 |
| Metric | VIK | KVUE |
|---|---|---|
| Price | $83.91 | $17.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $84.14 | $19.45 |
| AVG Volume (30 Days) | 2.8M | ★ 16.9M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.82% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $14.41 | $4.85 |
| Revenue Next Year | $14.16 | $2.63 |
| P/E Ratio | ★ $37.68 | $68.66 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.41 | $14.02 |
| 52 Week High | $92.00 | $24.36 |
| Indicator | VIK | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 43.41 |
| Support Level | $68.14 | $16.87 |
| Resistance Level | $87.00 | $17.32 |
| Average True Range (ATR) | 2.87 | 0.37 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 46.80 | 13.11 |
Viking Holdings Ltd is a travel company, with a fleet of 92 small ships, which view as floating hotels. It offers travel experiences on all seven continents in all three categories of the cruise industry river, ocean, and expedition cruising. The Group defines its products based on the type of cruise offering and language of the cruise service. The River segment provides river cruises outside the United States to English-speaking passengers. The Ocean segment offers ocean cruises to English-speaking passengers. Other include operating segments that are not individually reportable, consisting of expedition cruises for English-speaking passengers (Expedition), Mississippi River cruises for English-speaking passengers, and Viking China, which includes cruises for Mandarin.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.